Elevated plasma triglycerides (TG) and TG-rich lipoproteins (TGRLP), especially postprandial (pp) TGRLP, are emerging risk factors for atherothrombotic disease. However, little is known about the molecular basis for their interaction with cells of the artery wall or in the periphery. We identified and cloned a wholly unique receptor for dietary ppTGRLP, the apoB48 receptor (apoB48R), found in human monocyte-macrophages and in foam cells in arterial lesions. Now a mouse model, deficient in this receptor, has been created, and evidence demonstrates that in an atherogenic background the loss of the apoB48R reduces atherosclerosis significantly, further implicating it in macrophage foam cell formation and reduces peripheral uptake in tissues that normally express the receptor and elevates plasma cholesterol and triglycerides (TG). Therefore, using this new mouse model, we plan to determine its role in dietary lipoprotein metabolism and ppTGRLP uptake by cells in the periphery where the receptor is highly expressed (bone marrow, spleen, skeletal muscle and adipose). Furthermore, we will identify the molecular mechanisms and the extent to which ppTGRLP are atherogenic in mouse models of atherogenesis, including the apoE- and LDL R-deficient mice, crossed into the apoB48R-deficient mouse and in our newly developed apoB48R transgenic mice with enhanced tissue specific apoB48R expression in macrophages and liver (where it is not normally found) and we will evaluate the impact of the apoB48R on atherogenesis when animals are subjected to atherogenic and TG-elevating diets, thereby altering the postprandial mileau. We further plan to determine in vitro the molecular and cellular mechanisms by which the apoB48 R operates, that is, rapid, efficient accumulation of intracellular lipid. In vitro studies will identify the receptor recycling rates, endosomal/lysosomal trafficking, possible involvement of microtubules and/or microfilaments and rates of synthesis and degradation. The ligand-binding domain of the receptor will be sought as an eventual targeting site for intervention. Finally we will identify potential additional modifiers of macrophage pathobiology that may be exacerbated by the uptake of ppTGRLP via the apoB48R pathway by interfering in the normal cholesterol homeostasis, both production (HMGCoA reductase) and efflux (via ABC A1). The proposal uses the powerful techniques of mouse genetics coupled with dietary manipulations in vivo coupled with cell and molecular biology approaches in vitro aimed to answer key questions about the role of the apoB48 R and its interaction with ppTGRLP in health and disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL044480-15
Application #
6910881
Study Section
Metabolism Study Section (MET)
Program Officer
Applebaum-Bowden, Deborah
Project Start
1991-01-01
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
15
Fiscal Year
2005
Total Cost
$410,852
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Haraguchi, Go; Kobayashi, Yasushi; Brown, Matthew L et al. (2003) PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor. J Lipid Res 44:1224-31
Brown, Matthew L; Yui, Katsumasa; Smith, Jonathan D et al. (2002) The murine macrophage apoB-48 receptor gene (Apob-48r): homology to the human receptor. J Lipid Res 43:1181-91
Datta, G; Garber, D W; Chung, B H et al. (2001) Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res 42:959-66
Datta, G; Chaddha, M; Garber, D W et al. (2000) The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 39:213-20
Brown, M L; Ramprasad, M P; Umeda, P K et al. (2000) A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc Natl Acad Sci U S A 97:7488-93
Bradley, W A; Brown, M L; Ramprasad, M P et al. (1999) Antipeptide antibodies reveal interrelationships of MBP 200 and MBP 235: unique apoB-specific receptors for triglyceride-rich lipoproteins on human monocyte-macrophages. J Lipid Res 40:744-52
Gianturco, S H; Ramprasad, M P; Song, R et al. (1998) Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol 18:968-76
Li, X N; Grenett, H E; Benza, R L et al. (1997) Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 17:3215-23
Ramprasad, M P; Li, R; Bradley, W A et al. (1995) Human THP-1 monocyte-macrophage membrane binding proteins: distinct receptor(s) for triglyceride-rich lipoproteins. Biochemistry 34:9126-35
Ramprasad, M P; Li, R; Gianturco, S H et al. (1995) Purification of the human THP-1 monocyte-macrophage triglyceride-rich lipoprotein receptor. Biochem Biophys Res Commun 210:491-7

Showing the most recent 10 out of 14 publications